TVGN Tevogen Inc.
Listings ·
Nasdaq confirmed on September 29, 2026 that Tevogen meets the $50 million minimum market value of listed securities rule. The company had $1.1 million of cash at June 30, 2026, after cash used in operations of $12.3 million in 2025.
Tevogen received two Nasdaq notices in April 2026 saying it no longer meets the $50 million listed-securities market value requirement or the $15 million publicly held shares requirement. It has until October 13 and October 14, 2026 to regain compliance with each.
Nasdaq told Tevogen Bio Holdings on September 23, 2025 that its shares had closed below $1.00 for 30 consecutive business days, giving it until March 23, 2026 to regain compliance. Its 2024 annual report said the company was relying on $8.0 million of grant funding it had not yet received.
Tevogen can sell up to $50,000,000 of common stock through A.G.P./Alliance Global Partners, which is paid 3.0% of gross proceeds. The company's net tangible book value was negative $7.72 million at March 31, 2025, and buyers at the $1.25 reference price would face $1.07 a share of dilution.
Tevogen said a change in outside accounting providers in September 2024 left it needing more time. It will keep reporting material weaknesses in internal controls.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $11.1 million | $31.0 million |
| Net income (loss) | -$26.3 million | -$13.7 million |
| Cash from operations | -$12.3 million | -$12.0 million |
| Cash and equivalents | $0 | $0 |
Our latest story on this, dated Jul 3, 2025: "Tevogen Bio Holdings sets up $50,000,000 at-the-market stock program with A.G.P.". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 22, 2026: "Tevogen Bio Holdings (now Tevogen Inc.) gets two Nasdaq deficiency notices on market value". The story links the filing or release it is based on. Read the story.
Tevogen Inc. trades under the ticker TVGN on NASDAQ.
Tevogen Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Tevogen Inc. is 1860871. Its filings are on SEC EDGAR.
6,511,540 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Tevogen Inc. under United States.
Our directory classifies Tevogen Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Tevogen Inc. is US88165K2006.
aibio.space lists Tevogen Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Tevogen Inc. reported a net loss of $26.3 million for the fiscal year ended Dec 31, 2025, and used $12.3 million of cash in operations, per its annual report to the SEC.
$11.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
$1.1 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Tevogen, dated Sep 30, 2026: "Tevogen regains compliance with Nasdaq Global Market listing rules". Nasdaq confirmed on September 29, 2026 that Tevogen meets the $50 million minimum market value of listed securities rule. The company had $1.1 million of cash at June 30, 2026, after cash used in operations of $12.3 million in 2025. Source.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio